Jingjing Yang

Jingjing Yang

Auto-generated profile, based on publicly available information

Jingjing Yang

Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2017 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
WLWenjing Liang
Wenjing Liang
HMHui Ma
Hui Ma
LCLuxi Cao
Luxi Cao
WYWenjiang Yan
Wenjiang Yan
JYJingjing Yang
Jingjing Yang
Thiazide diuretics are widely used for the management of hypertension. In recent years, it has been actively debated that there is interchangeability of thiazide‐type diuretics hydrochlorothiazide and thiazide‐like diuretics including indapamide and chlorthalidone for the treatment of hypertension. With the purpose of seeking out the best thiazide diuretic for clinicians, we summarized the existing evidence on the two types of drugs and conducted a meta‐analysis on their efficacy in lowering blood pressure and effects on blood electrolyte, glucose and total cholesterol. Twelve trials were identified: five based on the comparison of indapamide versus hydrochlorothiazide and seven based on the chlorthalidone versus hydrochlorothiazide. In the meta‐analysis of blood pressure reduction, thiazide‐like diuretics seemed to further reduce systolic BP ([95% CI]; −5.59 [−5.69, −5.49]; P < 0.001) and diastolic BP ([95% CI]; −1.98 [−3.29, −0.66]; P = 0.003). Meanwhile, in the analysis of side effects, the incidence of hypokalemia ([95% CI]; 1.58 [0.80, 3.12]; P = 0.19), hyponatremia ([95% CI]; −0.14 [−0.57, 0.30], P = 0.54), change of blood glucose ([95% CI];0.13 [−0.16, 0.41], P = 0.39) and total cholesterol ([95% CI]; 0.13 [−0.16, 0.41], P = 0.39) showed that there is no statistical significant differences between the two groups of drugs. In conclusion, using thiazide‐like diuretics is superior to thiazide‐type diuretics in reducing blood pressure without increasing the incidence of hypokalemia, hyponatraemia and any change of blood glucose and serum total cholesterol.

16 February 2018 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
WLWenjing Liang
Wenjing Liang
QWQian Wang
Qian Wang
HMHui Ma
Hui Ma
WYWenjiang Yan
Wenjiang Yan
JYJingjing Yang
Jingjing Yang
Background/Aims: Fibroblast growth factor 2 (FGF2) plays a predominant role during angiogenesis in the adventitia and in atherosclerotic plaque. A dilemma exists, however, as to whether angiogenic stimulation by FGF2 for the prevention and treatment of atherogenesis is feasible. The aim of this study is to investigate the effect of the 18-kDa FGF-2 isoform on atherosclerosis progression in high-fat diet-fed apolipoprotein E knockout (ApoE-/-) mice. Methods: We established a model of atherosclerosis using ApoE and 18-kDa FGF-2 gene double knockout mice. They were randomly divided into three groups depending on the duration of diet: 8 weeks, 12 weeks and 16 weeks. Then, we studied the morphology and inflammatory factor staining in the atherosclerosis plaque of these mice. Results: Knockout of the 18-kDa FGF-2 isoform did not change the metabolic characteristics of the mice. Compared to the control group, knockout of the 18-kDa FGF-2 isoform significantly attenuated atherogenesis, reduced aortic plaques, reduced macrophage infiltration and suppressed oxidative stress in mice fed with a high fat diet at all-time points. Conclusions: 18-kDa FGF-2 aggravated the inflammatory reaction of atherosclerosis.

20 March 2020 in Coronary Artery Disease
Verified
Journal Article
Closed access
WYWenjiang Yan
Wenjiang Yan
SYShaozhong Yang
Shaozhong Yang
LCLiang Chen
Liang Chen
JYJingjing Yang
Jingjing Yang
Analgesics, particularly opioids, have been routinely used in the emergency treatment of ischemic chest pain for a long time. In the past two decades; however, several studies have raised the possibility of the harmful effects of opioid administration. In 2014, the American Heart Association (AHA)/American College of Cardiology Foundation (ACCF) changed the guidelines regarding the use of opioids from class IC to class IIb for non-ST elevation acute coronary syndrome. And in 2015, the European Society of Cardiology (ESC) guidelines incidentally noted the side effects of opioids. In ST-segment elevation myocardial infarction, both ESC and AHA/ACCF still recommend the use of opioids. Given the need for adequate pain relief in ischemic chest pain in the emergency setting, it is necessary to understand the adverse effects of analgesia, while still providing sufficiently potent options for analgesia. The primary purpose of this review is to quantify the effects of analgesics commonly used in the prehospital and emergency department in patients with ischemic chest pain.

22 May 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
XHXiaoxia Hu
Xiaoxia Hu
JKJing Kong
Jing Kong
TNTingting Niu
Tingting Niu
LCLiang Chen
Liang Chen
JYJingjing Yang
Jingjing Yang
We present a 55-year-old man with chest tightness and dyspnoea after activity lasting for 2 months who was diagnosed with single coronary artery (SCA) and presented with dilated cardiomyopathy (DCM) with the c.1858C > T mutation in the SCN5A gene. The computed tomography coronary angiogram (CTCA) showed congenital absence of the right coronary artery (RCA), and the right heart was nourished by the left coronary artery branch with no apparent stenosis. Transthoracic echocardiography (TTE) revealed enlargement of the left heart and cardiomyopathy. Cardiac magnetic resonance imaging (CMR) revealed DCM. Genetic testing showed that the c.1858C > T variant of the SCN5A gene could lead to Brugada syndrome and DCM. SCA is a rare congenital anomaly of the coronary anatomy, and this case reported as SCA accompanied by DCM is even rarer. We present a rare case of a 55-year-old man with DCM with the c.1858C > T (p. Arg620Cys)/c.1008G > A (p.(Pro336=) variant of the SCN5A gene, congenital absence of RCA, and c.990_993delAACA (p. Asp332Valfs*5) variant of the APOA5 gene. To our knowledge, this is the first report of DCM combined with the SCN5A gene mutation in SCA after searching the PubMed, CNKI and Wanfang databases.

20 July 2021
Verified
Conference Paper
Open access
JZJun Zhong
Jun Zhong
PZPing Zhang
Ping Zhang
JWJie Wu
Jie Wu
QLQiao Liu
Qiao Liu
JYJingjing Yang
Jingjing Yang
JFJingyun Fu
Jingyun Fu
First, to analyze the risk factors of hyperglycemia in Growth hormone-secreting pituitary adenoma(GHPA) by comparing clinical data, biochemical indexes, and imaging data. Second, to study the correlation between growth hormone receptor (GHR) gene polymorphism and hyperglycemia. The results of this study will help to evaluate the GHPA condition and choose effective treatment measures, reduce the GHPA clinical mortality and improve the prognosis of GHPA. From January 2014 to July 2020, we collected 120 patients 18-75 years old who were diagnosed with GHPA in the First Affiliated Hospital of Kunming Medical University. According to blood glucose levels, they were divided into hyperglycemia as the study group and normal blood glucose as a control group. The course of the disease, BMI, FPG, GH, HOMA-IR, and PBG was with statistically significant differences in hyperglycemia patients(P < 0.05).However,gender,age,PRL,The size of the tumor volume,HOMA-β,0'INS,120'INS,0'C-P,120'C-P,IGF-1 and HbA1c were with statistically significant differences(P > 0.05)compared with control group.In the study, The risk factors associated with hyperglycemia in GHPA were the course of the disease, BMI, GH, and FPG.In the study group, FPG was positively correlated with the size of the tumor volume and GH.PBG was positively correlated with FPG and HOMA-IR and negatively correlated with HOMA-β.In the subgroup analysis of the study group, FPG was with statistically significant differences (P=0.049). The results showed that FPG between the microadenoma group and the giant adenoma group was with statistically significant differences (P=0.019). However, PBG wasn't with statistically significant differences (P=0.133).In the present study, when we performed correlation analysis of risk factors and GHR genotype polymorphisms, we found that d3/d3GHR was significantly associated with BMI compared to f1/d3GHR (P=0.049), and d3/d3GHR explained 29.44% of the variation in BMI values;d3/d3GHR had a lower BMI value of 4.83kg/ m2.d3/d3GHR was not significantly correlated with GH (P=0.965), FPG (P=0.625), and the course of disease (P=0.755) compared to f1/d3GHR.